China“s Innovent drug outperforms Novo“s semaglutide in diabetes trial
2025.10.30 by CHEN Yang China’s Innovent Biologics said its dual receptor agonist Mastutide delivered stronger results than Novo Nordisk’s semaglutide (Ozempic) in a Phase III trial among Chinese patients with type 2 diabetes and obesity, signaling how Chinese drugmakers are narrowing the gap in the global obesity-drug race. After 32 weeks, 48 percent of patients […]
Diabetes remission possible with GLP-1 drugs, Italian study confirms
In a large real-world Italian cohort, GLP-1 receptor agonist therapy led to measurable rates of type 2 diabetes remission, depending on how remission was defined. The most pragmatic definition (Remission 3) was linked to improved glycemia, weight, and a lower risk of microvascular and cardiovascular events.
GLP-1 drugs effective for weight loss, but more independent studies needed
Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.
Eli Lilly partners with Walmart to sell weight-loss drug directly to patients nationwide
Patients will be able to access Eli Lilly’s weight-loss drug Zepbound at Walmart pharmacies nationwide through its direct-to-consumer program as soon as next month. The partnership between Eli Lilly and Company and Walmart, announced Wednesday, will allow people with a valid prescription to pick up single-dose vials of Zepbound at Walmart pharmacies nationwide or opt […]
The FDA Approved a GLP-1 Pill for Heart Health—Here’s What a Cardiologist Has to Say
Post Content
Can You Ask If Someone’s Taking a GLP-1?
Here’s what not to say—and how not to say it.
GLP-1 therapeutics: Their emerging role in alcohol and substance use disorders
Comments
3 GLP-1 updates
In October, GLP-1 manufacturers inked partnerships with big-box retailers to increase access as several studies indicate a low adherence rate for the expensive medications. Three updates on the GLP-1 drug class: 1. Prescriptions go unfilled Despite expanded approvals for conditions beyond obesity and Type 2 diabetes, the GLP-1 drug class is experiencing a drop in […]
GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies
Food Funct., 2025, Advance ArticleDOI: 10.1039/D5FO03273C, Review Article Yingzhe Luo, Huimin Xu, Yaqin Zhao, Biao Yang, Ying ZhangGLP-1 receptor agonists modulate tumor metabolism and immunity by restoring mitochondrial function, reversing the Warburg effect, and enhancing antitumor responses, offering therapeutic potential across cancers.To cite this article before page numbers are assigned, use the DOI form of […]
Recent Developments in Retinal Disease
(MedPage Today) — Thus far in 2025, notable developments in retinal disease have included several newsworthy associations with the widely used GLP-1 agonist drugs for diabetes and weight loss, a study of patient satisfaction with treatment for…